Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer

Commentary
Video
Conference|San Antonio Breast Cancer Symposium

Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.

Heather A. Parsons, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.

Related Videos
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
Benjamin Garmezy, MD
Jeffrey P. Townsend, PhD
Michael Iglesia, MD, PhD
Related Content
Hope S. Rugo, MD

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

May 16th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Erika Hamilton, MD

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

May 16th 2024
Article
Carol M. Mangione, MD, of UCLA Health

Updated Breast Cancer Screening Recommendations Pave the Way for a More Equitable Future

May 16th 2024
Article